Table of Contents Author Guidelines Submit a Manuscript
International Journal of Genomics
Volume 2015, Article ID 368979, 8 pages
http://dx.doi.org/10.1155/2015/368979
Review Article

Pharmacogenomics and Opioid Analgesics: Clinical Implications

Department of Medical Laboratories, Faculty of Health and Caring Professions, Technological Educational Institute of Athens, Athens, Greece

Received 14 October 2014; Revised 22 April 2015; Accepted 26 April 2015

Academic Editor: Shen Liang Chen

Copyright © 2015 Eugenia Yiannakopoulou. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. E. Evans and M. V. Relling, “Pharmacogenomics: translating functional genomics into rational therapeutics,” Science, vol. 286, no. 5439, pp. 487–491, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Siva, W. M. Yokoyama, and H. L. McLeod, “Pharmacogenetics in rheumatology: the prospects and limitations of an emerging field,” Rheumatology, vol. 41, no. 11, pp. 1273–1279, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Martínez, G. Blanco, J. M. Ladero et al., “Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use,” British Journal of Pharmacology, vol. 141, no. 2, pp. 205–208, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Pirmohamed, “Pharmacogenetics of idiosyncratic adverse drug reactions,” in Adverse Drug Reactions Handbook of Experimental Pharmacology, J. Uetrecht, Ed., pp. 478–491, Springer, 2010. View at Google Scholar
  5. A. de Capraris, G. Cinnella, A. Marolla et al., “Micro opioid receptor A118G polymorphism and post-operative pain: opioids' effects on heterozigous patients,” International Journal of Immunopathology and Pharmacology, vol. 24, no. 4, pp. 993–1004, 2011. View at Google Scholar · View at Scopus
  6. W.-Y. Chou, L.-C. Yang, H.-F. Lu et al., “Association of μ-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty,” Acta Anaesthesiologica Scandinavica, vol. 50, no. 7, pp. 787–792, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. W. Y. Chou, C. H. Wang, P. H. Liu, C. C. Liu, C. C. Tseng, and B. Jawan, “Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy,” Anesthesiology, vol. 105, no. 2, pp. 334–337, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. A. T. Sia, Y. Lim, E. C. P. Lim et al., “A118G single nucleotide polymorphism of human μ-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia,” Anesthesiology, vol. 109, no. 3, pp. 520–526, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. W. Zhang, J.-J. Yuan, Q.-C. Kan, L.-R. Zhang, Y.-Z. Chang, and Z.-Y. Wang, “Study of the OPRM1 A118G genetic polymorphism associated with postoperative nausea and vomiting induced by fentanyl intravenous analgesia,” Minerva Anestesiologica, vol. 77, no. 1, pp. 33–39, 2011. View at Google Scholar · View at Scopus
  10. P. Klepstad, T. T. Rakvåg, S. Kaasa et al., “The 118 A > G polymorphism in the human μ-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease,” Acta Anaesthesiologica Scandinavica, vol. 48, no. 10, pp. 1232–1239, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. A. V. Bortsov, R. C. Millikan, I. Belfer, R. L. Boortz-Marx, H. Arora, and S. A. McLean, “µ-opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer,” Anesthesiology, vol. 116, no. 4, pp. 896–902, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Hayashida, M. Nagashima, Y. Satoh et al., “Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype,” Pharmacogenomics, vol. 9, no. 11, pp. 1605–1616, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. U. A. Meyer, “Pharmacogenetics and adverse drug reactions,” The Lancet, vol. 356, no. 9242, pp. 1667–1671, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. W. W. Weber, “Populations and genetic polymorphisms,” Molecular Diagnosis, vol. 4, no. 4, pp. 299–307, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. R. A. Wilcox and H. Owen, “Variable cytochrome P450 2D6 expression and metabolism of codeine and other opioid prodrugs: implications for the Australian anaesthetist,” Anaesthesia and Intensive Care, vol. 28, no. 6, pp. 611–619, 2000. View at Google Scholar · View at Scopus
  16. K. Eckhardt, S. Li, S. Ammon, G. Schänzle, G. Mikus, and M. Eichelbaum, “Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation,” Pain, vol. 76, no. 1-2, pp. 27–33, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Persson, S. Sjostrom, I. Sigurdardottir, V. Molnar, M. Hammarlund-Udenaes, and A. Rane, “Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan,” British Journal of Clinical Pharmacology, vol. 39, no. 2, pp. 182–186, 1995. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Gaedigk, L. D. Bradford, K. A. Marcucci, and J. S. Leeder, “Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans,” Clinical Pharmacology & Therapeutics, vol. 72, no. 1, pp. 76–89, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Poulsen, L. Riishede, K. Brosen, S. Clemensen, and S. H. Sindrup, “Codeine in post-operative pain—study of the influence of sparteine phenotype and serum concentrations of morphine and morphine-6-glucuronide,” European Journal of Clinical Pharmacology, vol. 54, no. 6, pp. 451–454, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. D. G. Williams, A. Patel, and R. F. Howard, “Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability,” British Journal of Anaesthesia, vol. 89, no. 6, pp. 839–845, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Gasche, Y. Daali, M. Fathi et al., “Codeine intoxication associated with ultrarapid CYP2D6 metabolism,” The New England Journal of Medicine, vol. 351, no. 27, pp. 2827–2831, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Ciszkowski, P. Madadi, M. S. Phillips, A. E. Lauwers, and G. Koren, “Codeine, ultrarapid-metabolism genotype, and postoperative death,” The New England Journal of Medicine, vol. 361, no. 8, pp. 827–828, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Voronov, H. J. Przybylo, and N. Jagannathan, “Apnea in a child after oral codeine: a genetic variant—an ultra-rapid metabolizer,” Paediatric Anaesthesia, vol. 17, no. 7, pp. 684–687, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Madadi, G. Koren, J. Cairns et al., “Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine,” Canadian Family Physician, vol. 53, no. 1, pp. 33–35, 2007. View at Google Scholar · View at Scopus
  25. P. Madadi, C. J. D. Ross, M. R. Hayden et al., “Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study,” Clinical Pharmacology and Therapeutics, vol. 85, no. 1, pp. 31–35, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. L. E. Kelly, M. Rieder, J. van den Anker et al., “More codeine fatalities after tonsillectomy in North American children,” Pediatrics, vol. 129, no. 5, pp. e1343–e1346, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. K. R. Crews, A. Gaedigk, H. M. Dunnenberger et al., “Clinical pharmacogenetics implementation consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype,” Clinical Pharmacology & Therapeutics, vol. 91, no. 2, pp. 321–326, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. C. F. Samer, Y. Daali, M. Wagner et al., “The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone,” British Journal of Pharmacology, vol. 160, no. 4, pp. 907–918, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. K. K. Lemberg, T. E. Heiskanen, M. Neuvonen et al., “Does co-administration of paroxetine change oxycodone analgesia: an interaction study in chronic pain patients,” Scandinavian Journal of Pain, vol. 1, no. 1, pp. 24–33, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. T. N. Andreassen, I. Eftedal, P. Klepstad et al., “Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study,” European Journal of Clinical Pharmacology, vol. 68, no. 1, pp. 55–64, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. M. R. Hutchinson, A. Menelaou, D. J. R. Foster, J. K. Coller, and A. A. Somogyi, “CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes,” British Journal of Clinical Pharmacology, vol. 57, no. 3, pp. 287–297, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Madadi, D. Hildebrandt, I. Y. Gong et al., “Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions,” Pediatrics, vol. 126, no. 4, pp. e986–e989, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. H. F. Galley, A. Mahdy, and D. A. Lowes, “Pharmacogenetics and anesthesiologists,” Pharmacogenomics, vol. 6, no. 8, pp. 849–856, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. U. M. Stamer, K. Lehnen, F. Höthker et al., “Impact of CYP2D6 genotype on postoperative tramadol analgesia,” Pain, vol. 105, no. 1-2, pp. 231–238, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. H. G. Siew, R. Ismail, W. A. W. Adnan, and W. Zulmi, “Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics,” Molecular Diagnosis and Therapy, vol. 11, no. 3, pp. 171–181, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. O. Slanar, P. Dupal, O. Matouskova, H. Vondrackova, P. Pafko, and F. Perlik, “Tramadol efficacy in patients with postoperative pain in relation to CYP2D6 and MDR1 polymorphisms,” Bratislavské lekárske listy, vol. 113, no. 3, pp. 152–155, 2012. View at Google Scholar · View at Scopus
  37. G. Wang, H. Zhang, F. He, and X. Fang, “Effect of the CYP2D610 C188T polymorphism on postoperative tramadol analgesia in a Chinese population,” European Journal of Clinical Pharmacology, vol. 62, no. 11, pp. 927–931, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Kirchheiner, J. T. H. A. Keulen, S. Bauer, I. Roots, and J. Brockmöller, “Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol,” Journal of Clinical Psychopharmacology, vol. 28, no. 1, pp. 78–83, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. U. M. Stamer, F. Stüber, T. Muders, and F. Musshoff, “Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication,” Anesthesia & Analgesia, vol. 107, no. 3, pp. 926–929, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Elkalioubie, D. Allorge, L. Robriquet et al., “Near-fatal tramadol cardiotoxicity in a CYP2D6 ultrarapid metabolizer,” European Journal of Clinical Pharmacology, vol. 67, no. 8, pp. 855–858, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. S. H. Wong, M. A. Wagner, J. M. Jentzen et al., “Pharmacogenomics as an aspect of molecular autopsy for forensic pathology/toxicology: does genotyping CYP 2D6 serve as an adjunct for certifying methadone toxicity?” Journal of Forensic Sciences, vol. 48, no. 6, pp. 1406–1415, 2003. View at Google Scholar · View at Scopus
  42. O. Levran, E. Peles, S. Hamon, M. Randesi, M. Adelson, and M. J. Kreek, “CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction,” Addiction Biology, vol. 18, no. 4, pp. 709–716, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. M. A. Hamman, G. A. Thompson, and S. D. Hall, “Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C,” Biochemical Pharmacology, vol. 54, no. 1, pp. 33–41, 1997. View at Google Scholar
  44. B. L. Coffman, C. D. King, G. R. Rios, and T. R. Tephly, “The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268),” Drug Metabolism and Disposition, vol. 26, no. 1, pp. 73–77, 1998. View at Google Scholar · View at Scopus
  45. M. Holthe, P. Klepstad, K. Zahlsen et al., “Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A128 polymorphisms in cancer patients on chronic morphine therapy,” European Journal of Clinical Pharmacology, vol. 58, no. 5, pp. 353–356, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. D. S. Darbari, R. H. N. van Schaik, E. V. Capparelli, S. Rana, R. McCarter, and J. Van Den Anker, “UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease,” American Journal of Hematology, vol. 83, no. 3, pp. 200–202, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. K. Rouguieg, N. Picard, F.-L. Sauvage, J.-M. Gaulier, and P. Marquet, “Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes,” Drug Metabolism and Disposition, vol. 38, no. 1, pp. 40–45, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. H.-J. Park, H. K. Shinn, S. H. Ryu, H.-S. Lee, C.-S. Park, and J.-H. Kang, “Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans,” Clinical Pharmacology and Therapeutics, vol. 81, no. 4, pp. 539–546, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. L. Coulbault, M. Beaussier, C. Verstuyft et al., “Environmental and genetic factors associated with morphine response in the postoperative period,” Clinical Pharmacology & Therapeutics, vol. 79, no. 4, pp. 316–324, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. E. Kesimci, A. B. Engin, O. Kanbak, and B. Karahalil, “Association between ABCB1 gene polymorphisms and fentanyl's adverse effects in Turkish patients undergoing spinal anesthesia,” Gene, vol. 493, no. 2, pp. 273–277, 2012. View at Publisher · View at Google Scholar · View at Scopus